Amgen (AMGN) Receivables - Other (2013 - 2024)

Amgen's Receivables - Other history runs 8 years deep, the most recent figure standing at $198.0 million for Q4 2024.

• In Q4 2024, Receivables - Other fell 60.56% year-over-year to $198.0 million; the TTM figure through Dec 2024 stood at $198.0 million (down 60.56% YoY), while the FY2024 annual figure was $198.0 million, down 60.56% from the prior year.
• Receivables - Other was $198.0 million for Q4 2024 at Amgen, down from $502.0 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $780.0 million in Q4 2021 to a low of $129.0 million in Q4 2022.
• Historically, Receivables - Other has averaged $438.4 million across 5 years, with a median of $502.0 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Receivables - Other plunged 83.46% in 2022, then jumped 289.15% in 2023.
• A 5-year view of Receivables - Other shows it stood at $583.0 million in 2020, then soared by 33.79% to $780.0 million in 2021, then slumped by 83.46% to $129.0 million in 2022, then surged by 289.15% to $502.0 million in 2023, then sank by 60.56% to $198.0 million in 2024.
• The last three Receivables - Other figures came in at $198.0 million (Q4 2024), $502.0 million (Q4 2023), and $129.0 million (Q4 2022), per Business Quant data.